UGT1A1 Antibody (N-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS: 1
- PROTOCOLS
- BACKGROUND
Application
| IHC-P, IF, WB, E |
---|---|
Primary Accession | P22309 |
Other Accession | NP_000454.1 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 59591 Da |
Antigen Region | 65-90 aa |
Gene ID | 54658 |
---|---|
Other Names | UDP-glucuronosyltransferase 1-1, UDPGT 1-1, UGT1*1, UGT1-01, UGT11, Bilirubin-specific UDPGT isozyme 1, hUG-BR1, UDP-glucuronosyltransferase 1-A, UGT-1A, UGT1A, UDP-glucuronosyltransferase 1A1, UGT1A1, GNT1, UGT1 |
Target/Specificity | This UGT1A1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 65-90 amino acids from the N-terminal region of human UGT1A1. |
Dilution | IF~~1:10~50 WB~~1:1000 IHC-P~~1:10~50 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | UGT1A1 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | UGT1A1 (HGNC:12530) |
---|---|
Synonyms | GNT1, UGT1 |
Function | [Isoform 1]: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:12181437, PubMed:15472229, PubMed:18004206, PubMed:18004212, PubMed:18719240, PubMed:19830808, PubMed:23288867). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:12181437, PubMed:18004206, PubMed:18004212). Catalyzes the glucuronidation of endogenous estrogen hormones such as estradiol, estrone and estriol (PubMed:15472229, PubMed:18719240, PubMed:23288867). Involved in the glucuronidation of bilirubin, a degradation product occurring in the normal catabolic pathway that breaks down heme in vertebrates (PubMed:17187418, PubMed:18004206, PubMed:19830808). Also catalyzes the glucuronidation the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties (PubMed:18052087, PubMed:19545173). Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist losartan, a drug which can inhibit the effect of angiotensin II (PubMed:18674515). Involved in the biotransformation of 7-ethyl-10- hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan (PubMed:12181437, PubMed:18004212, PubMed:20610558). |
Cellular Location | Endoplasmic reticulum membrane; Single-pass membrane protein. Cytoplasm, perinuclear region |
Tissue Location | [Isoform 1]: Expressed in liver, colon and small intestine. Not expressed in kidney, esophagus and skin |
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites. This gene is part of a complex locus that encodes several UDP-glucuronosyltransferases. The locus includes thirteen unique alternate first exons followed by four common exons. Four of the alternate first exons are considered pseudogenes. Each of the remaining nine 5' exons may be spliced to the four common exons, resulting in nine proteins with different N-termini and identical C-termini. Each first exon encodes the substrate binding site, and is regulated by its own promoter. The preferred substrate of this enzyme is bilirubin, although it also has moderate activity with simple phenols, flavones, and C18 steroids. Mutations in this gene result in Crigler-Najjar syndromes types I and II and in Gilbert syndrome.
References
Italia, K.Y., et al. Clin. Biochem. 43 (16-17), 1329-1332 (2010) :
Justenhoven, C., et al. Breast Cancer Res. Treat. 124(1):289-292(2010)
Hu, M., et al. Pharmacogenet. Genomics 20(10):634-637(2010)
Sai, K., et al. Br J Clin Pharmacol 70(2):222-233(2010)
Kilic, I., et al. Int J Clin Pharmacol Ther 48(8):504-508(2010)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.